Keymed Biosciences Inc. (2162.HK) HKSE

60.30

+0.9(+1.52%)

Updated at January 15 01:33PM

Currency In HKD

Valuation

Market Cap7.6B
Enterprise Value7.94B
P/E Ratio-54.69
PEG Ratio-1.09
Price/Sales Ratio18.09
Price/Book Ratio4.41
Enterprise/Revenue18.01
Enterprise/EBITDA-50.25

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-0.3
Operating Margin-0.4

Management Effectiveness

Return On Assets-0.06
Return On Equity-0.09

Income Statement

Revenue428.12M
Revenue/Share3.32
Gross Profit415.92M
EBITDA-574.46M
Net Income-515.24M
Diluted EPS-1.97

Balance Sheet

Total Cash2.8B
Total Cash/Share10.56
Total Debt872.3M
Total Debt/Equity0.27
Current Ratio3.95
Book Value Per Share12.16

Price History

52-Week Change108.52
52-Week High80
52-Week Low27.2
Moving Average 50 Days57.72
Moving Average 200 Days56.83

Statistics

Average Volume2.08M
Shares Outstanding294.6M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A